Marker Therapeutics Awarded $16.2M Product Development Research Grant From Cancer Prevention And Research Institute Of Texas
Benzinga Newsdesk 7 hours ago
News
Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphomaCPRIT award builds on encouraging Phase 1 clinical results, with additional
Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma
CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year
Independent scientific, clinical, and commercial review reinforces the potential of MT-601 in relapsed large B-cell lymphoma
HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support the advancement of the Company’s lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma (LBCL) following treatment with CD19-directed chimeric antigen receptor (CAR)-T cells.
